Antagonism of the orexigenic peptide ghrelin, for example, was identified to inhibit growth hormone secretion, gastric emptying, and decrease postprandial glucose levels in humans [50], making it a promising therapeutic target in obesity. Here, GH1 is linked to obesity due to melanocortin 4 receptor deficiency.